AXIM Obtains More Financing for Its Cannabinoid Therapies for MS and Bowel Diseases
News
AXIM Biotechnologies has secured an additional $4 million in institutional financing to advance clinical trials of its cannabinoid therapies for multiple sclerosis (MS) and irritable bowel syndrome. Some of the ... Read more